Leo Meriranta

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Tyrosine Kinase

Diffuse Large B Cell Lymphoma

Chronic Lymphocytic Leukemia

Top Venues

Blood cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppa, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood advances 8 (2) (2024)
Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppa, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood advances 8 (2) (2024)
Leo Meriranta, Selma Sorri, Kanutte Huse, Xiaonan Liu, Ivana Spasevska, Sadia Zafar, Iftekhar Chowdury, Olli Dufva, Eerika Sahlberg, Luka Tandaric, Marja-Liisa Karjalainen-Lindsberg, Marko M Hyytiäinen, Markku Varjosalo, June Helen Myklebust, Sirpa Leppa
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma. Blood cancer discovery 5 (5) (2024)
Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppa, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood advances 8 (2) (2024)
Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppa, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood advances 8 (2) (2024)
Leo Meriranta, Selma Sorri, Kanutte Huse, Xiaonan Liu, Ivana Spasevska, Sadia Zafar, Iftekhar Chowdury, Olli Dufva, Eerika Sahlberg, Luka Tandaric, Marja-Liisa Karjalainen-Lindsberg, Marko M Hyytiäinen, Markku Varjosalo, June Helen Myklebust, Sirpa Leppa
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma. Blood cancer discovery (2024)
Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppa, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood advances 8 (2) (2024)
Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppa, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood advances (2023)
Leo Meriranta, Amjad Alkodsi, Annika Pasanen, Maija Lepistö, Parisa Mapar, Yngvild Nuvin Blaker, Judit Meszaros Jørgensen, Marja-Liisa Karjalainen-Lindsberg, Idun Fiskvik, Lars Tore G Mikalsen, Matias Autio, Magnus Björkholm, Mats Jerkeman, Øystein Fluge, Peter de Nully Brown, Sirkku Jyrkkiö, Harald Holte, Esa Pitkänen, Pekka Ellonen, Sirpa Leppa
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood 139 (12) (2022)